Mechanism of Insulin-Resistant in Lean Non-Diabetics

Completed · Phase 1

Conditions studied: Insulin Resistance, Insulin Sensitivity, Type 2 Diabetes

In brief

The study is designed to test the following primary hypothesis: * Aerobic exercise training will improve insulin sensitivity in insulin resistant subjects through changes in the major cellular signaling pathways and and/or their regulators. Accordingly, the proposed study is designed to accomplish the following specific aims: * Quantitate how exercise training improves insulin sensitivity and decreases cardiovascular risk factors in a general population of lean, nondiabetic, insulin resistant subjects. Effects on known cardiovascular risk factors including blood pressure and serum lipoproteins will be evaluated. Change in regional adiposity will also be measured * Determine the effects of a program of regular aerobic exercise on in the insulin receptor signaling pathway. Biopsies of vastus lateralis muscle from insulin resistant subjects will be obtained before and after a hyperinsulinemic glucose clamp. This procedure will take place in the untrained state and after exercise training. The investigators will measure changes in the insulin receptor and the activity of the major components of the intracellular insulin signaling pathway. The investigators will also look intracellular proteins that regulate this signaling pathway.

Key facts

Study ID

NCT00970099

Run by

University of California, San Francisco

People needed

149

Starts

2004-02-01

Expected to finish

2009-12-01

Last updated by the study team

2014-01-23

Who can join

Age: 20 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Men and women aged 20-50
• No regular exercise for past 2 years

You may not qualify if…

• Diabetes, Cardiovascular disease, Pregnant or lactating females,BMI >27
• Medications that may interfere with carbohydrate metabolism - glucocorticoids, adrenergic agonists, ACE inhibitors, alpha blockers, diuretics, beta blockers, oral contraceptives, HMG CoA reductase inhibitors
• History of epilepsy, cancer, hepatitis, active infection, active Graves' disease, cystic fibrosis, sickle cell anemia, peripheral vascular disease, cerebrovascular disease, asthma
• Any medical condition that in the opinion of the investigator will interfere with safe completion of the trial
• Inability to give informed consent
• Prior participation in a clinical trial that could potentially alter insulin sensitivity: e.g., use of new insulin sensitizers
• HIV seropositive
• Anemia (Hgb < 12 g/dl)

Where it is running

• Ucsf Gcrc — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.